“So, you know, as Gary pointed out in the commentary, we reiterated our guidance for this fiscal year of 47.5% to 5% organic revenue growth and high-single-digit realized EPS growth in the back half of the year.”

In context

“on. I promise I'll keep it to one. You know, as you guys are moving into fiscal ‘26, obviously there's Hugo, CAS is accelerating, you know, Inceptive doing well, Micra, et cetera. So there's a lot of moving parts, I know it's only Q3, but would it be fair to assume that the base algorithm would call it mid-single-digit-ish growth and then high-singles in the bottom line, that that's a fair assumption moving into fiscal ‘26. Also can we go back as an exit rate in Q4? Is that a fair assumption? Geoff Martha: Sure, Patrick, thanks for the question. Yes, you know, we'll obviously like you've been, we'll give FY ‘26 guidance on our Q4 call, but yes, our objective is unchanged. We're committed to doing the things that we need to do to drive profitable growth and operating leverage at Medtronic. So, you know, as Gary pointed out in the commentary, we reiterated our guidance for this fiscal year of 47.5% to 5% organic revenue growth and high-single-digit realized EPS growth in the back half of the year. And as we look into the future, you know, we think that this we're still committed to that to that LRP that you outlined. Patrick Wood: Fantastic, thanks take the question. Ryan Weispfenning: Thanks, Patrick. Next question, please, Brad. Brad Welnick: We'll take the next question from Larry Biegelsen at Wells Fargo. Larry, please go ahead. Larry you there? Larry Biegelsen: Hey, I'm here. I'm here guys. Can you hear me? Yes, can you hear me? Brad Welnick: Yeah, we can. Larry Biegelsen: Sorry about that. Sorry I forgot to unmute. So thanks for taking the question guys. I wanted to ask Sean a question on AF Solutions, which was obviously a bright spot in Q3. So, Sean, talk about the drivers of the acceleration in Q4? And how you're thinking about fiscal ‘26 and, you know, specifically the ra”